We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Aura Biosciences (AURA) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Aura Biosciences, Inc. (AURA - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Aura Biosciences, Inc. is one of 891 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aura Biosciences, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AURA's full-year earnings has moved 12.7% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, AURA has gained about 36.5% so far this year. Meanwhile, stocks in the Medical group have lost about 6.7% on average. This means that Aura Biosciences, Inc. is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Biodesix, Inc. (BDSX - Free Report) . The stock is up 89% year-to-date.
The consensus estimate for Biodesix, Inc.'s current year EPS has increased 3.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Aura Biosciences, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 436 individual stocks and currently sits at #93 in the Zacks Industry Rank. On average, stocks in this group have gained 1.3% this year, meaning that AURA is performing better in terms of year-to-date returns.
Biodesix, Inc., however, belongs to the Medical Services industry. Currently, this 62-stock industry is ranked #82. The industry has moved -10% so far this year.
Aura Biosciences, Inc. and Biodesix, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Aura Biosciences (AURA) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Aura Biosciences, Inc. (AURA - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Aura Biosciences, Inc. is one of 891 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Aura Biosciences, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AURA's full-year earnings has moved 12.7% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the latest available data, AURA has gained about 36.5% so far this year. Meanwhile, stocks in the Medical group have lost about 6.7% on average. This means that Aura Biosciences, Inc. is performing better than its sector in terms of year-to-date returns.
One other Medical stock that has outperformed the sector so far this year is Biodesix, Inc. (BDSX - Free Report) . The stock is up 89% year-to-date.
The consensus estimate for Biodesix, Inc.'s current year EPS has increased 3.5% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Aura Biosciences, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 436 individual stocks and currently sits at #93 in the Zacks Industry Rank. On average, stocks in this group have gained 1.3% this year, meaning that AURA is performing better in terms of year-to-date returns.
Biodesix, Inc., however, belongs to the Medical Services industry. Currently, this 62-stock industry is ranked #82. The industry has moved -10% so far this year.
Aura Biosciences, Inc. and Biodesix, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.